Dr. Alexander Dobranowski reports
MCI ONEHEALTH PARTNERS WITH UMED TO ACCELERATE CLINICAL RESEARCH
MCI Onehealth Technologies Inc. and uMed, the United Kingdom based provider of a leading automated patient recruitment platform, have formed a partnership that will increase patient access to international research studies and accelerate enrolment and improve retention in clinical trials. MCI is uMed's first Canadian partner.
"MCI's collaboration with uMed will open a new subset of research that emphasizes real-world evidence and patient-reported information. MCI firmly believes that patient-facing technology is a core component for increasing access to health care and for making care more personalized," said Dr. Alexander Dobranowski, founder and chief executive officer of MCI. "MCI is already uniquely positioned in that we use technology to screen clinical data efficiently and compliantly to flag patients as potential participants for research trials. Once potential participants are flagged from among our more than three million patient records, uMed provides a highly efficient and incredibly fast method for contacting, enrolling and ongoingly engaging these MCI patients for any current clinical trial and for future relevant trials. This collaboration creates another innovative avenue by which MCI's clinical insights as a service program can help optimize patient care, provide access to meaningful clinical trial opportunities, and bring value to life sciences stakeholders and health systems."
uMed connects health care professionals and their patients with groundbreaking research opportunities. Its digital patient recruitment platform enables health care professionals to participate in more research with minimal additional workload, providing its patients with better access to studies that are highly relevant to their specific condition.
uMed's ability to capture patient-reported outcomes and real-world evidence is in demand for advancing clinical insights and fosters patient empowerment. Its platform and approach are fully compliant with all relevant requirements for consent, privacy, data security and research ethics for clinical research, additionally allowing for opportunities to more easily and compliantly re-engage patients for follow-up or related trials.
"We're thrilled to partner with innovators like MCI for our entry into Canada. Our two companies are aligned in the vision of how access to research can help optimize health for specific patients and more broadly across populations. Faster and more customizable cohorts in interventional and non-interventional clinical trials lead to better care options sooner and more cost-efficiently," said Dr. Matt Wilson, chief executive officer of uMed. "In MCI, we see a partner that not only shares uMed's driven commitment to supporting effective, efficient clinical research but also a company with the existing clinical data lake to immediately utilize the uMed platform for significant outcomes."
In keeping with its objective to be a pre-eminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. MCI's audience for clinical insights continues to grow in Canada and the United States and will further benefit from collaboration with international leader uMed.
About MCI Onehealth Technologies Inc.
MCI is a health care technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality and reduce health care costs. As part of the health care community for over 30 years, MCI operates one of Canada's leading primary care networks with approximately 280 physicians and specialists, serves more than one million patients annually, and had nearly 300,000 telehealth visits last year, including on-line visits through mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. MCI provides data insights as a service in six categories: rare disease; complex major medical/chronic; patient cohort building; clinical trial recruitment; synthetic health data; and bespoke insights. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centred around acquiring technology and health services that complement the company's current road map.
We seek Safe Harbor.
© 2023 Canjex Publishing Ltd. All rights reserved.